Methods
This report is a retrospective chart review of one patient with MGRS and
immunotactoid glomerulopathy. The patient reviewed this manuscript and
provided written informed consent for the review of her medical records
and publication of the results, per the Declaration of Helsinki.
Bortezomib, dexamethasone, and rituximab (BDR)3:
Cycle 1: bortezomib 1.3 mg/m2 IV on days 1, 4, 8, and 11; 21-day cycle.
Cycles 2-5: bortezomib 1.6 mg/m2 IV on days 1, 8, 15, and 22; 35-day
cycle.
Cycles 2 and 5 only: dexamethasone 40 mg PO on days 1, 8, 15, and 22;
rituximab 375 mg/m2 IV on days 1,8, 15, and 22; 35-day cycle.
Contact corresponding author for data acquisition and microscopy
details.